Author/Authors :
López-Vilella, R. Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Sánchez, J. Sanz Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Lázaro, I. Sánchez Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Sule, E. Marques Physiotherapy Department- University of Valencia, Valencia, Spain , Soriano, J. Rueda Adult Congenital Heart Disease Unit- Cardiology Department- Hospital Universitario y Politécnico La Fe, Valencia, Spain , Bonet, L. Almenar Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Abstract :
Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists.
However, the lack of treatment to reverse the effect of direct oral anticoagulants has
limited its use in some patients who require rapid reversal of anticoagulation, as those included
in the transplant waiting list. Idarucizumab is a recently approved drug to reverse the anticoagulant
effect of dabigatran. However, the clinical experience when using this drug is scarce.
Herein, we present a clinical case on anticoagulation reversal with idarucizumab to perform
heart and lung transplantation in a patient with Eisenmenger syndrome.
